These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22116549)

  • 1. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy.
    Gupta M; Han JJ; Stenson M; Wellik L; Witzig TE
    Leukemia; 2012 Jun; 26(6):1356-64. PubMed ID: 22116549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2.
    Gupta M; Ansell SM; Novak AJ; Kumar S; Kaufmann SH; Witzig TE
    Blood; 2009 Oct; 114(14):2926-35. PubMed ID: 19641186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
    Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
    Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
    Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R
    Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chidamide induces apoptosis in DLBCL cells by suppressing the HDACs/STAT3/Bcl‑2 pathway.
    Zhang H; Chi F; Qin K; Mu X; Wang L; Yang B; Wang Y; Bai M; Li Z; Su L; Yu B
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33649847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
    Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
    J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.
    Song X; Wang J; Zheng T; Song R; Liang Y; Bhatta N; Yin D; Pan S; Liu J; Jiang H; Liu L
    Mol Cancer; 2013 Oct; 12(1):114. PubMed ID: 24093956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms.
    Gao SM; Chen CQ; Wang LY; Hong LL; Wu JB; Dong PH; Yu FJ
    Exp Hematol; 2013 Mar; 41(3):261-70.e4. PubMed ID: 23111066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258.
    Vallo S; Mani J; Stastny M; Makarević J; Juengel E; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    Invest New Drugs; 2013 Apr; 31(2):265-72. PubMed ID: 22801803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
    Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A.
    Togi S; Kamitani S; Kawakami S; Ikeda O; Muromoto R; Nanbo A; Matsuda T
    Biochem Biophys Res Commun; 2009 Feb; 379(2):616-20. PubMed ID: 19121623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation.
    Chuang MJ; Wu ST; Tang SH; Lai XM; Lai HC; Hsu KH; Sun KH; Sun GH; Chang SY; Yu DS; Hsiao PW; Huang SM; Cha TL
    PLoS One; 2013; 8(9):e73401. PubMed ID: 24023871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.
    Brault L; Menter T; Obermann EC; Knapp S; Thommen S; Schwaller J; Tzankov A
    Br J Cancer; 2012 Jul; 107(3):491-500. PubMed ID: 22722314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The STAT3 inhibitor WP1066 reverses the resistance of chronic lymphocytic leukemia cells to histone deacetylase inhibitors induced by interleukin-6.
    Lu K; Fang XS; Feng LL; Jiang YJ; Zhou XX; Liu X; Li PP; Chen N; Ding M; Wang N; Zhang J; Wang X
    Cancer Lett; 2015 Apr; 359(2):250-8. PubMed ID: 25636517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression and clinical significance of tyrosine-phosphorylated STAT3 in ALK+ and ALK- anaplastic large cell lymphoma.
    Khoury JD; Medeiros LJ; Rassidakis GZ; Yared MA; Tsioli P; Leventaki V; Schmitt-Graeff A; Herling M; Amin HM; Lai R
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3692-9. PubMed ID: 14506160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.